Skip to main content
. 2017 Mar 2;23:1106–1115. doi: 10.12659/MSM.901744

Table 1.

Epidemiological data of patients with white dot syndromes.

Disease Number of patients, sex, age Inititial visual acuity Final visual acuity Unilateral Bilateral CMO/ ERM/CMO+ERM CNV/Macularscar Fibrosis Damage of macular RPE Glaucoma Cataract Treatment
MFCPU 21 (17W, 4M) age 24–77 Count finger to 16/20 Count finger to 20/20 3 18 2/7/3 0 0 0 3 6

  • – All patients-topical steroidal/nonsteroidal, mydriatics,

  • – Oral prednisone in 13 patients

  • – Antiglaucomatous in 3
MFC 8 (6W, 2M) age 25–37 Count finger to 20/20 Count finger to 20/20 4 4 0 1/5 0 0 0 0

  • – 1- PDT

  • – Oral prednisone/cyclosporine in one
PIC 8 (5W, 3M) age 18–43 1/100 To 18/20 1/100 to 18/20 2 6 0 3/2 0 0 0 0

  • – 3-iniection of Mucugen in 1 patient

  • – 4 oral prednisone in past medical history
birdshot 8 (5W, 3M) age 23–70 Count finger to 20/20 Count finger to 20/20 1 7 3/2/1 0 0 0

  • – All patients topical steroidal/nonsteroidal

  • – 2 oral prednisone

  • – 2 prednisone + cyclosporin
AMPPE 7 (6W, 1M) age 21–51 4/20 To 20/20 4/20 to 20/20 3 4 0 1 0 7 0 0

  • – 1-PDT

  • – 2 oral prednisone 2 oral prednisone/acyclovir)

  • – 2 oral acyclovir
SFU 4 (2W, 2M) age 26–37 Count finger to 20/20 Count finger to 20/20 1 3 0 0/4 4 0 0 0 2 oral prednisone
Serpiginous 2 M aged 24 and 44 4/20 to 8/20 4/20 to 8/20 0 2 0 0/1 1 1 0 0 1 oral prednisone
1 oral prednisone + cyclosporin
MEWDS 2W, 1M (19–33) 4/20 20/20 3 0 0 0 0 3 0 0 Topical non-steroidal antinflammatory
AAOR W 24 4/20 16/20 1 0 0 0 0 1 0 0 Oral prednisone + acyclovir